DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 80
SponsorQueen Mary Hospital, Hong Kong
About this trial
To study the correlation between novel DIC markers and thrombin generation parameters with thrombotic and hemorrhagic complications of patients on ECMO support.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≧ 18; AND
Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital or Tuen Mun Hospital in Hong Kong; AND
Require either veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support.
Disqualifiers
Patients who are on central VA-ECMO support; OR
Patients with missing clinical data; OR
Patients with pre-existing thromboembolism requiring long term anticoagulation prior to ECMO cannulation; OR
Post-operative admissions
Trial population
Patients requiring ECMO support
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
DIC markers and Thrombin Generation Parameters
Diagnostic testObservation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
Treatment groups
50 Participants
are divided into 2 treatment groupsGroup A: Adult Intensive Care Unit, Queen Mary Hospital1 intervention
Group B: Department of Intensive Care Unit, Tuen Mun Hospital1 intervention
Trial outcomes
Primary outcomes
1
Composite of thrombotic and hemorrhagic events
Thrombotic events include circuit-related thrombosis (e.g. oxygenator failure requiring circuit change) OR Non-circuit-related thrombosis (e.g. new pulmonary embolism or deep vein thrombosis while on ECMO. Hemorrhagic events include bleeding at critical sites or requiring interventions.
Time frame
From the start of ECMO support to the end of ECMO support (which can be variable, typically around 5 days to 1 week)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov